Zanvastro Kit
Product Images NDC 71860-304

6 FDA label images from Ionis Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Zanvastro (NDC 71860-304). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ionis Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Zilganersen Sodium Structural Formula (Figure 01)

Zilganersen Sodium Structural Formula (Figure 01)
Chemical structure diagram showing multiple polymer chains with nucleic acid components featuring sodium ions and sulfur-phosphorus linkages. The structure includes chemical groups with notation R representing OCH2CH2OCH3, indicative of a modified oligonucleotide structure.*
FDA Label Image

Mean Change From Baseline In Plasma Gfap (geometric Mean Ratio ± Se) In Patients Treated With Zilganersen 50 mg Or Control (Figure 02)

Mean Change From Baseline In Plasma Gfap (geometric Mean Ratio ± Se) In Patients Treated With Zilganersen 50 mg Or Control (Figure 02)
A line graph illustrating the geometric mean ratio plus standard error over a period of 61 weeks comparing ZANVASTRO 50 mg and a control group. The y-axis represents the geometric mean ratio, ranging from 0.6 to 1.4, and the x-axis indicates weeks from Baseline to 61. Two lines represent the groups: ZANVASTRO 50 mg with squares and the control group with circles, alongside corresponding sample sizes at each time point displayed below the graph.*
FDA Label Image

Mean Percent Change In Gait Speed From Baseline In Stratum 1 Patients Treated With Zanvastro 50 mg Or Control (Figure 03)

Mean Percent Change In Gait Speed From Baseline In Stratum 1 Patients Treated With Zanvastro 50 mg Or Control (Figure 03)
A line graph showing percent change in gait speed (mean ± SEM) over 61 weeks, comparing ZANVASTRO 50 mg to a control group. The ZANVASTRO group maintains near baseline gait speed, while the control group shows a decline. Sample sizes at various weeks are noted for each group. A p-value of 0.041 indicates statistical comparison between the groups.*
FDA Label Image

Carton-1 (Figure 04)

Carton-1 (Figure 04)
Carton label for Zanvastro (zilganersen) injection kit containing 56 mg/2.8 mL (20 mg/mL) for intrathecal use only. The label includes dosage and administration instructions, contents details including vial volumes and ingredients, storage conditions, and distributor Ionis Pharmaceuticals Inc. Address and NDC 71860-304-01 are shown. The kit contains one vial of Zanvastro injection and one vial of accompanying artificial cerebrospinal fluid (aCSF) diluent.*
FDA Label Image

Label-01 (Figure 05)

Label-01 (Figure 05)
Label for Zanvastro (zilganersen) injection showing strength as 56 mg/2.8 mL (20 mg/mL) in a single-dose vial. The label indicates intrathecal use only, requires dilution, and is distributed by Ionis Pharmaceuticals Inc. The label includes the NDC 71860-104-01 and barcode details.*
FDA Label Image

Label-02 (Figure 06)

Label-02 (Figure 06)
Diluent label for Zanvastro (zilganersen) kit, featuring Artificial Cerebrospinal Fluid (aCSF) diluent in a 21 mL single-dose vial. The label includes caution about excess diluent and indicates distribution by Ionis Pharmaceuticals Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.